Table 1.
Characteristics of Patients with SLE According to Obesity Category (N(%)
| Overall | Not Obese | Obesea | P | |
|---|---|---|---|---|
| Number (%) | 142 | 96 (66.9) | 47 (33.1) | |
| Demographic | ||||
| Age, mean ± SD | 47.9 ± 12.3 | 47.3 ± 12.7 | 48.9 ± 11.7 | 0.47 |
| Race | 0.03 | |||
| White | 92 (64.8) | 68 (71.6) | 24 (51.1) | |
| Black | 20 (14.1) | 9 (9.5) | 11 (23.4) | |
| Asian | 18 (12.7) | 14 (14.7) | 4 (8.5) | |
| Latino | 25 (17.6) | 15 (15.8) | 10 (21.3) | |
| Unspecified or other | 4 (2.8) | 1 (1.1) | 3 (6.4) | |
| Education beyond high school | 123 (86.6) | 86 (90.5) | 37 (78.7) | 0.05 |
| Poverty level incomeb | 21 (15.3) | 8 (8.7) | 13 (28.9) | 0.002 |
| Health related | ||||
| Cardiovascular Diseasec | 5 (3.5) | 3 (3.2) | 2 (4.3) | 0.74 |
| Diabetes Mellitus on treatment | 8 (5.6) | 2 (2.1) | 6 (12.8) | 0.01 |
| SLE disease duration, years | 15.5 ± 8.9 | 14.9 ± 8.4 | 16.9 ± 9.9 | 0.21 |
| C-reactive protein, mean ± SD | 4.2 ± 7.6 | 3.2 ± 7.0 | 6.2 ± 8.4 | <0.01 |
| Smoking, current | 8 (5.6) | 6 (6.3) | 2 (4.3) | 0.62 |
| Smoking, ever | 53 (37.6) | 37 (39.0) | 16 (34.8) | 0.63 |
| Medication Used | ||||
| Glucocorticoid | 63 (45.3) | 42 (45.2) | 21 (45.7) | 0.96 |
| Prednisone dose ≥ 7.5 mg/day | 29 (20.1) | 18 (19.4) | 11 (23.9) | 0.53 |
| Hydroxychloroquine | 63 (44.4) | 44 (46.3) | 19 (40.4) | 0.51 |
| Oral DMARDe | 50 (35.2) | 35 (36.8) | 15 (31.9) | 0.56 |
| Cyclophosphamide | 7 (4.9) | 7 (7.4) | 0 (0.0) | 0.06 |
| Rituximab | 5 (3.5) | 5 (5.3) | 0 (0.0) | 0.12 |
Except where indicated otherwise, values are number (%). P-values were calculated using chi-squared test for categorical measures, t-test for normally distributed continuous measures, and Wilcoxon-rank sum for skewed continuous measures.
a
Defined as fat mass index ≥ 13 kg/m2.
b
Household income ≤ 125% of the federal poverty level.
c
History of transient ischemic attack, stroke, or myocardial infarction.
d
Report of use within the last 12 months.
e
Disease Modifying Antirheumatic Drugs – includes azathioprine, mycophenolate mofetil, methotrexate, and tacrolimus.